At the Cowen presentation the CEO spoke like approval for Refractive Bladder Cancer was fait accompli. The larger picture of course is the application of the small protein adherence technology to other cancers. Interesting is some other Biotechs that have similar small protein adherence technology in other applications such as Refractive Prostate Cancer seem to be moving up in unison. Notably Sophiris Bio. It seems the large Bio investors are impressed with this new technology. Really it is a ground breaking effort and very promising. Also infinitely cheaper and easier to manufacture on a large scale than others.
News 
Market Data 
Discover 
